EUVIMEDEUVIMED entdecken
Crossref

L26/P-664 Comparison of segmental aneuploidy rates between two preimplantation genetic testing for aneuploidy (PGT-A) platforms. An age-stratified analysis of 4240 blastocysts

A. Mania, C. Engelbrecht, I. Sarris, Y. Beebeejaun

Human Reproduction · 01.07.2026 · 41 (Supplement_1)

DOI: 10.1093/humrep/deag083.994 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Human Reproduction, online erschienen am 08.07.2026. Verfasst von A. Mania und 3 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Study question Do reported rates of segmental aneuploidy (SA) differ between different PGT-A platforms after accounting for maternal age? Summary answer Segmental aneuploidy rates differed significantly between platforms, with Platform A demonstrating lower rates than Platform B, independent of maternal age at the time of biopsy. What is known already Detection of segmental aneuploidy in PGT-A is highly dependent on multiple technical and analytical parameters, including biopsy quality, whole-genome amplification performance, sequencing depth, and bioinformatic copy-number calling algorithms. Variation in segmentation methods, noise filtering, and laboratory-specific reporting thresholds substantially influence the sensitivity and specificity of segmental aneuploidy detection. As a consequence, the reported prevalence, size distribution, and classification of segmental abnormalities vary considerably between laboratories and testing platforms. This inter-laboratory variability limits biological comparability across studies and complicates the interpretation and clinical application of PGT-A results, particularly when segmental abnormalities are used to inform embryo selection. Study design, size, duration This retrospective cohort study evaluated PGT-A results from 4240 blastocyst-stage embryos analysed at a single clinical centre using two commercially available genetic testing platforms. Embryos were biopsied and tested as part of routine clinical care. Data were collected over multiple treatment cycles between 2019 and 2025, and results were analysed to compare reported segmental aneuploidy rates between two platforms while accounting for differences in maternal age at the time of biopsy. Participants/materials, setting, methods A total of 4240 blastocysts undergoing PGT-A were analysed using either Platform A (n = 1190; mean maternal age 38.88 years) or Platform B (n = 3050; mean maternal age 41.39 years). Embryos were classified according to each laboratory’s reporting criteria, with segmental mosaic findings incorporated with segmental aneuploids. The primary outcome was the proportion of embryos classified as segmental aneuploid. An analysis of covariance (ANCOVA) was performed. Main results and the role of chance The proportion of embryos classified as segmental aneuploid differed significantly between the two PGT-A platforms. Platform A demonstrated a lower segmental aneuploidy rate compared with Platform B (2.7% [32/1190] vs 6.6% [202/3050]). In the ANCOVA model, both testing platform (F(1, 4237) = 27.9, p < .001) and maternal age at biopsy (F(1, 4237) = 17.8, p < .001) were independently associated with segmental aneuploidy classification, and the overall model was statistically significant (F(2, 4237) = 21.7, p < .001). The testing platform accounted for a greater proportion of explained variance than maternal age, indicating that inter-platform differences in segmental aneuploidy classification were not attributable to age alone. Although homogeneity of variance was not met, the large sample size and strength of the observed effects support the robustness of these findings. This difference in segmental aneuploids between two platforms suggests that the disparity in reported segmental aneuploidy rates is unlikely to be attributable to chance alone. These findings indicate a substantial inter-platform difference in segmental aneuploidy reporting under routine clinical testing conditions. Limitations, reasons for caution This study was retrospective and relied on platform-specific analytical and reporting criteria, which may limit direct biological comparability of segmental aneuploidy classifications. Clinical outcomes were not evaluated. Wider implications of the findings Significant inter-platform differences in reported segmental aneuploidy rates persist after adjustment for maternal age, suggesting that analytical and reporting criteria play a major role in segmental abnormality classification. These findings underscore the need for greater standardization of segmental aneuploidy definitions to improve inter-laboratory comparability and clinical interpretation of PGT-A results. Trial registration number No

Zitieren

APA

Mania, A., Engelbrecht, C., Sarris, I., & Beebeejaun, Y. (2026). L26/P-664 Comparison of segmental aneuploidy rates between two preimplantation genetic testing for aneuploidy (PGT-A) platforms. An age-stratified analysis of 4240 blastocysts. Human Reproduction, 41(Supplement_1). https://doi.org/10.1093/humrep/deag083.994

Vancouver

Mania A, Engelbrecht C, Sarris I, Beebeejaun Y. L26/P-664 Comparison of segmental aneuploidy rates between two preimplantation genetic testing for aneuploidy (PGT-A) platforms. An age-stratified analysis of 4240 blastocysts. Human Reproduction. 2026;41(Supplement_1). doi:10.1093/humrep/deag083.994

BibTeX
@article{Mania2026,
  author = {Mania, A. and Engelbrecht, C. and Sarris, I. and Beebeejaun, Y.},
  title = {L26/P-664 Comparison of segmental aneuploidy rates between two preimplantation genetic testing for aneuploidy (PGT-A) platforms. An age-stratified analysis of 4240 blastocysts},
  journal = {Human Reproduction},
  year = {2026},
  volume = {41},
  number = {Supplement_1},
  doi = {10.1093/humrep/deag083.994}
}
Kostenlos starten →